Institut Curie and LEO Pharma Launch Artificial Intelligence Project to Identify Risks Predisposing to Thrombosis in Cancer Patients
Cancer patients have a 4-fold increased risk of developing Thromboembolic Vein Threat, or thrombosis, which is characterized by the formation of a clot within the venous system during their treatment.
Cancer is in itself one of the most common risk factors for VTE due to several factors:
- Cancer itself, since blood tends to coagulate more easily in the cancer patient, which leads to the risk of clot formation.
- Central venous catheters that are often placed in patients to facilitate the administration of chemotherapy,
- Certain anti-cancer treatments (chemotherapy, hormonal treatments, radiotherapy, surgery).
Since its creation, LEO Pharma has always been involved in the field of thrombosis by developing new molecules to treat or prevent thromboembolic diseases. The objective of this retrospective study, called DASTO, expected in the course of 2019, is to assess the extent to which "Data Science" or "Data Science" can complement the physician's experience in helping to understand how some known factors, and other unknown factors, can cause cancer patients to develop thrombosis. If this is the case, new recommendations to prevent the development of these thromboses could be considered as well as the identification of one or more profiles of patients at risk. In order to meet this challenge, LEO Pharma supports Institut Curie researchers and clinicians initiative to develop new innovative approaches to artificial intelligence.
For Dr. Alain Livartowski, Data Director of the Hospital Group at Institut Curie: "Institut Curie has been working for many years on this medical issue, but the use of new technologies in data science could improve burden of thromboembolic disease in patients followed in oncology. By bringing together the expertise of clinicians from the Institut Curie (anesthesiologist and pulmonologist) and Institut Curie's data department, this partnership could meet an unmet medical need".
According to Dr. Nadia Spiess, Thrombosis Medical Director at LEO Pharma: "With its support for Institut Curie, LEO Pharma is continuing its commitment to advance research on the links between cancer and thrombosis. Today, the risk of thrombosis is often underestimated in France, the prevention and management of patients are complex and require new data to understand what are the risk factors to take into account. The purpose of the DASTO project is to clarify these issues."
Amaury Martin, Director of Technology transfer and Industrial Partnerships Office of Institut Curie and Director of the Carnot Institute Curie Cancer concludes: "This agreement between a pharmaceutical company and Institut Curie (Carnot Curie Cancer) is an emblematic example of the strategy of Institut Curie in the field of data analysis. Institut Curie is positioning itself as a reference player in the development and application of new technologies aimed at improving the care of patients".